Tag: acute bacterial skin and skin structure infections market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Acute Bacterial Skin And Skin Structure Infections Market Grown from 2024 to 2025?

The market size for acute bacterial skin and skin structure infections has seen a significant surge in the past few years. It is projected to escalate from $11.75 billion in 2024 to $13.03 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.9%. The market expansion in the past was driven by innovation in the healthcare sector, economic conditions, patient population dynamics, advancements in diagnostic techniques, and innovation in clinical trials.

What Growth Rate Is Anticipated for the Acute Bacterial Skin And Skin Structure Infections Market in the Coming Years?

The market for acute bacterial skin and skin structure infections is anticipated to witness significant expansion in the forthcoming years, with its value expected to surge to $18.99 billion by 2029 at a 9.9% CAGR. The anticipated growth over the forecast period is attributable to global epidemiological influences, the introduction of new therapies in the market, fast diagnostic tools, a patient-focused methodology, and evolving treatment guidelines. Key trends during the forecast period encompass the demographics of the patient population, concerns pertaining to antibiotic resistance, the advent of improved treatment tactics, the prevalence of methicillin-resistant staphylococcus aureus (MRSA), and an emphasis on outpatient care.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Who Are the Leading Companies in the Acute Bacterial Skin And Skin Structure Infections Market?

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

What Are the Key Drivers of the Acute Bacterial Skin And Skin Structure Infections Market?

The surge in skin infections is anticipated to fuel the growth of the acute bacterial skin and skin structure infections market. These infections, caused by microorganisms including bacteria, fungi, or viruses, can create uncomfortable symptoms as they invade and multiply within the skin. The escalating number of skin infections generates more demand for therapeutic solutions, antibiotics, and innovative treatments that address acute bacterial skin and skin structure infections, thereby enabling patient access to top-tier care and health results. For instance, the World Health Organization noted in March 2023 that about 1.8 billion people worldwide experience skin conditions at any given time. Around 10% of these cases are Neglected Tropical Diseases (NTDs), with fungal and bacterial infections making up 34% and 23% respectively, often resulting in high death rates. Consequently, the escalating incidence of skin infections fuels the growth trajectory of the acute bacterial skin and skin structure infections market. An uptick in chronic diseases is predicted to spur the growth of the acute bacterial skin and skin structure infections market. Chronic diseases encompass prolonged medical conditions that typically progress at a slow pace and persist for a considerable time. These diseases, which often last for years or even a lifetime, usually don’t resolve on their own. The proliferation of chronic diseases propels the acute bacterial skin and skin structure infections market by increasing the chance of bacterial skin infections, thereby requiring more treatments, hospital stays, specialized healthcare, research, patient education, health expenditures, and individualized interventions. In September 2022, the World Health Organization reported 41 million deaths, accounting for 74% of deaths from non-communicable or chronic diseases worldwide annually. These included 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Hence, the growing prevalence of chronic diseases is a key driver for the growth of the acute bacterial skin and skin structure infections market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13282&type=smp

What Are the Key Market Segments in the Acute Bacterial Skin And Skin Structure Infections Industry?

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route Of Administration: Oral, Parenteral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

What Are the Latest Trends in the Acute Bacterial Skin And Skin Structure Infections Market?

Leading firms in the acute bacterial skin and skin structure infections market are adopting a strategic approach of introducing innovative single-dose treatments such as Dalbonova, in an effort to strengthen their market position. Dalbonova is a single-dose therapy designed to provide both effectiveness and convenience, enabling patients to accomplish their anticipated outcomes with a single powerful dose of 1500 mg that is administered just once. For example, BDR Pharmaceuticals Internationals Pvt. Ltd., a pharmaceutical company from India renowned for its speciality in API (active pharmaceutical ingredient) and formulation therapeutic areas, including acute bacterial skin and skin structure infections, introduced the Dalbonova injection to the market in August 2023. By providing a single-dose treatment, the Dalbonova Injection minimizes the potential for hospital-acquired diseases and removes the necessity for hospital admissions. This product is specifically for treating acute bacterial skin and skin structure infections (ABSSSI) initiated by specific gram-positive microorganisms and is recommended for patients of all age groups, including newborns.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

What Are the Key Regional Markets in the Acute Bacterial Skin And Skin Structure Infections Industry?

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13282

This Report Delivers Insight On:

1. How big is the acute bacterial skin and skin structure infections market, and how is it changing globally?

2. Who are the major companies in the acute bacterial skin and skin structure infections market, and how are they performing?

3. What are the key opportunities and risks in the acute bacterial skin and skin structure infections market right now?

4. Which products or customer segments are growing the most in the acute bacterial skin and skin structure infections market?

5. What factors are helping or slowing down the growth of the acute bacterial skin and skin structure infections market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the acute bacterial skin and skin structure infections industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Milestones in the Acute Bacterial Skin And Skin Structure Infections Market’s Growth Trajectory From 2025 To 2034?

A swift increase has been observed in the market size of acute bacterial skin and skin structure infections in the recent few years. It is expected to escalate from $11.75 billion in 2024 to a substantial figure of $13.03 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.9%. The exponential growth during the historic period can be traced back to advancements in the healthcare industry, economic influences, trends in patient population, progression in diagnostic techniques, and innovative clinical trials.

The market size of acute bacterial skin and skin structure infections is projected to experience robust growth in the coming years, reaching $18.99 billion in 2029 with a compound annual growth rate (CAGR) of 9.9%. This expected growth over the forecast period can be linked to worldwide epidemiological factors, the introduction of new therapies into the market, quick diagnostic tools, a patient-oriented approach, and changing treatment guidelines. Primary trends during this forecast period encompass demographic changes in patient populations, worry over antibiotic resistance, improvements in treatment plans, the rate of methicillin-resistant staphylococcus aureus (MRSA) instances, and a focus on outpatient care.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Acute Bacterial Skin And Skin Structure Infections Market?

As skin infections become more common, they are expected to stimulate the expansion of the market for acute bacterial skin and skin structure infections. These infections occur when microorganisms such as bacteria, fungi, or viruses invade and multiply within the skin, causing a variety of symptoms and discomfort. The growing frequency of skin infections increases the need for therapeutic solutions, antibiotics, and innovative treatments to combat acute bacterial and skin structure infections, ensuring patients receive the highest quality care and outcomes. According to a March 2023 report from the World Health Organization, a specialized agency of the United Nations based in Switzerland, approximately 1.8 billion people worldwide suffer from skin conditions at any given time. Neglected tropical diseases account for about 10% of these cases, with fungal infections representing 34% and bacterial infections 23%, often resulting in high mortality rates. This growing prevalence of skin infections, therefore, is projected to fuel the expansion of the market for acute bacterial skin and skin structure infections. An escalating incidence of chronic diseases is also set to spur the growth of the acute bacterial skin and skin structure infections market. Chronic diseases are long-term medical conditions that typically progress slowly and persist for a long period. These conditions, often lasting for years or even a lifetime, usually do not resolve on their own. The escalating incidence of chronic diseases impacts the acute bacterial skin and skin structure infections market by heightening the risk of bacterial skin infections, necessitating more treatments, hospital stays, specialized care, research, public awareness, healthcare spending, and tailored interventions for affected individuals. A report from the World Health Organization in September 2022 indicated that there were 41 million deaths globally due to non-communicable diseases (NCDs) or chronic diseases, which represent 74% of all deaths annually. These included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the escalating prevalence of chronic diseases propels the growth of the acute bacterial skin and skin structure infections market.

Which Key Market Segments Comprise the Acute Bacterial Skin And Skin Structure Infections Market and Drive Its Revenue Growth?

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route Of Administration: Oral, Parenteral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13282&type=smp

Which Areas Are Leading Regions in the Acute Bacterial Skin And Skin Structure Infections Market Expansion Across the Globe?

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering the Acute Bacterial Skin And Skin Structure Infections Market Direction?

Leading businesses in the acute bacterial skin and skin structure infections sector are honing in on the development of unique single-dose therapies like Dalbonova to secure a competitive advantage in the market. Dalbonova offers both convenience and efficacy, enabling patients to fulfill their treatment objectives with a single potent dose of 1500 mg. For example, BDR Pharmaceuticals Internationals Pvt. Ltd., an Indian company specializing in the active pharmaceutical ingredient (API) and formulation therapeutic segments, which includes acute bacterial skin and skin structure infections, introduced Dalbonova injection in August 2023. This one-time therapy for acute bacterial skin and skin structure infections (ABSSSI) lessens the probability of acquiring hospital-borne illnesses by offering a single-dose treatment, thereby negating the necessity for hospitalization. The medicine is formulated to mitigate ABSSSI triggered by certain gram-positive organisms in patients across all age groups, including newborns.

View the full report here:

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

How Is the Acute Bacterial Skin And Skin Structure Infections Market Conceptually Defined?

Acute bacterial skin and skin structure infections (ABSSSIs) are a type of skin infection caused by bacteria that affect the skin and underlying tissues, leading to symptoms such as redness, swelling, pain, and warmth in the affected area. Medical interventions, such as antibiotic treatment, are used to prevent complications and promote healing in mild to severe infections.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13282

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Primary Drivers Are Supporting the Continued Market Growth of theAcute Bacterial Skin And Skin Structure Infections Market?

The mounting incidence of skin ailments is anticipated to boost the expansion of the acute bacterial skin and skin structure infections market. Skin maladies are physicians where microbes like bacteria, fungi, or viruses infiltrate and multiply within the skin, resulting in various symptoms and discomfort. The surge in skin infections necessitates more robust therapeutic responses, antibiotics, and innovative remedies for harsh bacterial and skin structure infections, guaranteeing patients receive the highest quality care and outcomes. For example, in March 2023, the World Health Organization, a specialized UN agency based in Switzerland, reported that approximately 1.8 billion people worldwide are afflicted with skin disorders at any given time. Neglected tropical diseases account for about 10% of these cases, with 34% being fungal infections and 23% bacterial infections, often culminating in high fatality rates. Hence, the increasing occurrence of skin maladies will escalate the growth of the acute bacterial skin and skin structure infections market. The surge in chronic diseases frequency is projected to fuel the growth of the acute bacterial skin and skin structure infections market. Chronic diseases are persistent medical conditions that usually progress slowly and endure over an extensive period. These illnesses persist for years, perhaps even a lifetime, and seldom resolve independently. Chronic diseases’ proliferation stimulates the acute bacterial skin and skin structure infections market by boosting the probability of developing bacterial skin infections, necessitating expanded treatments, hospitalizations, specialized care, study, public consciousness, healthcare expenditure, and customized interventions for those affected. For example, in September 2022, as per World Health Organization, a specialized UN agency based in Switzerland, there were 41 million deaths globally, constituting 74% of all deaths resultant from non-communicable (chronic) diseases each year. The death toll included 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the mounting incidence of chronic diseases propels the growth of the acute bacterial skin and skin structure infections market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

#How Will the CAGR of the Acute Bacterial Skin And Skin Structure Infections Market Influence Its Overall Growth by 2034?

The market size of acute bacterial skin and skin structure infections has witnessed a substantial expansion recently. The figure is forecasted to rise from $11.75 billion in 2024 to an estimated $13.03 billion in 2025, with a compound annual growth rate (CAGR) of 10.9%. The historic growth has been attributed to advancements in the healthcare industry, economical aspects, patient population patterns, advancements in diagnostic methodology, and innovation in clinical trials.

The market size for acute bacterial skin and skin structure infections is anticipated to witness robust expansion in the coming years, reaching $18.99 billion by 2029 with a compound annual growth rate (CAGR) of 9.9%. The expected escalation during the forecast period is due to global epidemiological dynamics, the introduction of new therapeutic procedures, swift diagnostic tools, patient-focused approach, and changing treatment protocols. Key trends during the forecast period encompass demographic shifts in patient population, worries about antibiotic resistance, progression in treatment methodologies, occurrence of methicillin-resistant staphylococcus aureus (mrsa), and an emphasis on outpatient care.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13282

How Are Consumer Market Innovations Shaping the Current and Future Landscape of theAcute Bacterial Skin And Skin Structure Infections Market?

Prominent firms in the acute bacterial skin and skin structure infections market are concentrating their efforts on creating innovative single-dose treatments like Dalbonova to secure a competitive advantage. Dalbonova is a unique treatment that is both convenient and efficient, allowing patients to reach their treatment goals with only one powerful 1500 mg dosage. As an illustration, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd, a pharmaceutical firm based in India that concentrates on API (active pharmaceutical ingredient) and treatment protocols for ailments such as acute bacterial skin and skin structure infections, unveiled their Dalbonova injection. This single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI) serves to decrease the prevalence of illnesses acquired in hospitals by providing a one-time treatment option that negates the need for hospitalization. It is specially formulated to combat ABSSSI triggered by certain gram-positive microorganisms, catering to patients of all ages, including newborns.

Who Are the Key Market Players Influencing the Growth of the Corn and Acute Bacterial Skin And Skin Structure Infections Industry?

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

Which Key Market Segments Comprise the Acute Bacterial Skin And Skin Structure Infections Market and Drive Its Revenue Growth?

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route Of Administration: Oral, Parenteral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13282&type=smp

Which Regions Are Emerging as Leaders in the Acute Bacterial Skin And Skin Structure Infections Market?

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Acute Bacterial Skin And Skin Structure Infections Market 2025, By The Business Research Company:

Taste Masking And Taste Assessment Services And Technologies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/taste-masking-and-taste-assessment-services-and-technologies-global-market-report

Antibacterial Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antibacterial-products-global-market-report

Double-Sided Masking Tapes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/double-sided-masking-tapes-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the acute bacterial skin and skin structure infections market right now?

The market size of acute bacterial skin and skin structure infections has swiftly expanded in the past few years. It is forecasted to increase from $11.75 billion in 2024 to a considerable $13.03 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.9%. Factors responsible for the growth during the historic period include innovations in the healthcare industry, economic aspects, trends in the patient population, advancements in diagnostic techniques, and progressive clinical trial methodologies.

How fast Is the acute bacterial skin and skin structure infections market expected to grow, and what’s its future value?

The market for acute bacterial skin and structure infections is anticipated to witness robust expansion in the coming years, with its value projected to reach $18.99 billion in 2029, thanks to a compound annual growth rate (CAGR) of 9.9%. The predicted surge during the forecast period can be ascribed to worldwide epidemiological aspects, the introduction of new therapeutic methods, quick diagnostic tools, a patient-oriented strategy, and revised treatment guidelines. Noteworthy trends for the anticipated period consist of demographics of the patient community, concerns about antibiotic resistance, advancements in treatment approaches, the commonness of methicillin-resistant staphylococcus aureus (mrsa), and emphasis on outpatient care.

Get your acute bacterial skin and skin structure infections market report here!

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

What are the leading drivers of growth in the acute bacterial skin and skin structure infections market?

An increase in skin infections is anticipated to fuel the expansion of the acute bacterial skin and skin structure infections market. Skin infections occur when harmful microorganisms such as bacteria, fungi, or viruses invade the skin, causing a range of symptoms and discomfort. As these skin infections rise, it enhances the demand for therapeutic solutions, antibiotics, and innovative treatments to manage acute bacterial and skin structure infections, ensuring optimal patient care and results. For example, as per the World Health Organization in March 2023, around 1.8 billion people worldwide experience skin conditions at any given time. Neglected tropical diseases (NTDs) account for roughly 10% of these, with fungal infections comprising 34% and bacterial infections 23%, often resulting in high death rates. Therefore, the surge in skin infections is set to fuel the expansion of the acute bacterial skin and skin structure infections market. A growing trend of chronic diseases is projected to spur the acute bacterial skin and skin structure infections market. Chronic diseases are long-term medical conditions that typically progress slowly and last over an extended period. They are often enduring or lifelong and generally do not reverse independently. The spike in such diseases escalates the risk of bacterial skin infections, thereby requiring an increase in treatments, hospitalizations, specialized care, research, public awareness, healthcare expenditure, and custom interventions for those affected. For instance, as per the World Health Organization in September 2022, there were 41 million deaths globally, constituting 74% of deaths caused by non-communicable diseases (NCDs) or chronic diseases annually. Deaths included 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the growing occurrence of chronic diseases is set to stimulate the growth of the acute bacterial skin and skin structure infections market.

What are the key segments defining the acute bacterial skin and skin structure infections market?

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route Of Administration: Oral, Parenteral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Who are the key players steering the development of the acute bacterial skin and skin structure infections market?

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

What emerging trends are influencing the growth of the acute bacterial skin and skin structure infections market?

Leading firms in the acute bacterial skin and skin structure infections market are pioneering innovative single-dose treatments like Dalbonova, as a strategy to establish market dominance. Dalbonova provides the dual advantage of convenience and efficiency, enabling patients to reach their targeted outcomes with a single administration of a potent 1500 mg dose. For example, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd, an Indian pharmaceutical entity specializing in API (active pharmaceutical ingredient) and formulation therapeutic sectors inclusive of acute bacterial skin and skin structure infections, introduced the Dalbonova injection, a one-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). This Dalbonova Injection minimizes the likelihood of hospital-related infections by providing a one-dose treatment, thereby eliminating hospital admissions. Created to combat ABSSSI triggered by specific gram-positive microorganisms, it can be used on patients of every age bracket, including neonates.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13282

Which regions are most influential in expanding the acute bacterial skin and skin structure infections market?

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Taste Masking And Taste Assessment Services And Technologies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/taste-masking-and-taste-assessment-services-and-technologies-global-market-report

Antibacterial Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antibacterial-products-global-market-report

Double-Sided Masking Tapes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/double-sided-masking-tapes-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Acute Bacterial Skin And Skin Structure Infections Market During the Forecast Period, and Why?

In recent times, the market size for acute bacterial skin and skin structure infections has seen rapid expansion. The market is projected to increase from $11.75 billion in 2024 to $13.03 billion in 2025, signaling a compound annual growth rate (CAGR) of 10.9%. The historic growth is driven by factors like innovation in healthcare industry, economic variables, patient population dynamics, progress in diagnostic techniques, and novel approaches to clinical trials.

In the coming years, the market for acute bacterial skin and skin structure infections is anticipated to witness substantial growth. Its value is projected to rise to $18.99 billion by 2029, with a compound annual growth rate (CAGR) of 9.9%. Factors such as global epidemiological conditions, introduction of new therapies, swift diagnostic instruments, a patient-centered approach, and changing treatment protocols contribute to this projected growth during the forecast period. The forecast period is also expected to be impacted by trends including demographic shifts in patient population, anxiety about antibiotic resistance, progress in treatment plans, an increased prevalence of methicillin-resistant staphylococcus aureus (mrsa), and a heightened emphasis on outpatient care.

What Strategic Factors Are Influencing the Accelerated Growth of the acute bacterial skin and skin structure infections Market?

The escalating incidence of skin infections is anticipated to fuel the expansion of the acute bacterial skin and skin structure infections market in the future. These infections occur when various microorganisms, including bacteria, fungi, or viruses, proliferate within the skin, resulting in an array of symptoms and discomfort. As skin infections increase, this elevates demand for therapeutic solutions, antibiotics, and novel treatments to tackle acute bacterial and skin structure infections. This ensures that patients have access to high-quality care and outcomes. For example, as reported by the World Health Organization in March 2023, nearly 1.8 billion individuals worldwide are affected by skin conditions at any given time. Of these, neglected tropical diseases constitute about 10%, with 34% accounted for by fungal and 23% by bacterial infections, frequently leading to high fatality rates. Therefore, the increasing incidence of skin infections is expected to stimulate the expansion of the acute bacterial skin and skin structure infections market.

Acute Bacterial Skin And Skin Structure Infections Market Driver: Increasing Prevalence Of Chronic Diseases To Drive The Growth Of Acute Bacterial Skin And Skin Structure Infections Market

 

Request Your Free Acute Bacterial Skin And Skin Structure Infections Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Which Companies Are Poised to Shape the Future of the Acute Bacterial Skin And Skin Structure Infections Market?

Major companies operating in the acute bacterial skin and skin structure infections market report are:

• Pfizer Inc._x000D_

• AbbVie Inc._x000D_

• Novartis AG_x000D_

• Abbott Laboratories_x000D_

• Fresenius SE & Co. KGaA_x000D_

What Are the Latest Innovations and Trends Influencing the Acute Bacterial Skin And Skin Structure Infections Market?

Major players in the acute bacterial skin and skin structure infections market are concentrating on the development of innovative single-dose treatments like Dalbonova, to maintain their competitiveness. This single-dose therapy, Dalbonova, allows for efficiency and convenience, enabling patients to attain their intended results with a single powerful 1500 mg dose. For example, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based company specializing in API (active pharmaceutical ingredient) and formulation therapeutic segments such as acute bacterial skin, and skin structure infections, unveiled Dalbonova injection. This particular single-dose therapy is for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Dalbonova injection potentially minimizes the likelihood of contracting diseases in hospitals by providing a single-dose solution and cutting the need for hospitalization. Its purpose is to counter acute bacterial skin and skin structure infections (ABSSSI) resulting from specific gram-positive organisms in patients encompassing all age groups, including newborns.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

How Are Key Segments Defining the Competitive Landscape of the Acute Bacterial Skin And Skin Structure Infections Market?

The acute bacterial skin and skin structure infections market covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients

3) By Route Of Administration: Oral, Parenteral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections

What Regions Are Contributing Significantly to the Growth of the Acute Bacterial Skin And Skin Structure Infections Market?

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Scope and Reach of the Acute Bacterial Skin And Skin Structure Infections Market Defined?

Acute bacterial skin and skin structure infections (ABSSSIs) are a type of skin infection caused by bacteria that affect the skin and underlying tissues, leading to symptoms such as redness, swelling, pain, and warmth in the affected area. Medical interventions, such as antibiotic treatment, are used to prevent complications and promote healing in mild to severe infections.

Browse Through More Similar Reports By The Business Research Company:

Taste Masking And Taste Assessment Services And Technologies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/taste-masking-and-taste-assessment-services-and-technologies-global-market-report

Antibacterial Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/antibacterial-products-global-market-report

Double-Sided Masking Tapes Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/double-sided-masking-tapes-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: